FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma, and a weekly injection is a potential new treatment option for polycythemia vera. In addition, adding adjuvant nivolumab improved disease‐free survival for patients with high‐risk locally advanced HNSCC, and switching to camizestrant prolonged PFS for patients with ER‐positive, HER2‐negative advanced breast cancer and an ESR1 mutation.